TipRanksStock Market NewsBerenberg Bank Maintains a Hold Rating on Aprea Therapeutics (APRE)

Berenberg Bank Maintains a Hold Rating on Aprea Therapeutics (APRE)

Berenberg Bank analyst Esther Hong maintained a Hold rating on Aprea Therapeutics (APREResearch Report) today and set a price target of $4.00. The company’s shares closed last Friday at $2.34.

According to TipRanks.com, Hong is ranked 0 out of 5 stars with an average return of -22.2% and a 16.7% success rate. Hong covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Aldeyra Therapeutics, and Axsome Therapeutics.

Currently, the analyst consensus on Aprea Therapeutics is a Hold with an average price target of $4.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on Aprea Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $9.45 million. In comparison, last year the company had a GAAP net loss of $12.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.

Read More on APRE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More